Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | The importance of QoL in guiding myeloma therapy

Karthik Ramasamy • 24 Mar 2019
EBMT 2019
General Multiple Myeloma

Karthik Ramasamy, PhD, from Oxford University Hospitals, Oxford, UK, emphasizes the importance of factoring in the quality of life (QoL) of patients to guide therapy. Dr Ramasamy was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

More from Karthik Ramasamy

1:17
Novel agents to improve outcomes for patients with multiple myeloma in the salvage setting
Karthik Ramasamy • 20 Dec 2023
2:42
Optimizing maintenance therapy in multiple myeloma: an analysis from the PREAMBLE registry
Karthik Ramasamy • 20 Dec 2023
2:05
RADAR: guiding treatment for NDMM with MRD and genetic risk
Karthik Ramasamy • 20 Dec 2023
2:25
OxCOM: monitoring monoclonal gammopathies for progression to active myeloma
Karthik Ramasamy • 20 Dec 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals